Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

- PMLiVE

Patient engagement – a journey of health activation

Listening to patients and HCPs helps strike the right notes to deliver harmony across engagement and activation

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director

Apkarian most recently served as executive vice president, group management director at Humancare

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

Havas Lynx appoints Ayesha Walawalkar as chief strategy officer

Walawalkar most recently served as chief strategy officer, international brands at MullenLowe Global, part of IPG

- PMLiVE

Advertising For Women’s Health: Breaking Taboos and Driving Change

Our strategist Stephanie Goley, MSc, PhD takes a fascinating look at how advertising is breaking down stigmas around areas of women's health such as menstruation and menopause - and helping...

11 London

Dave Miller on Biotechs image

Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

Genesis Research Group

- PMLiVE

Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

Petauri Evidence

- PMLiVE

AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

Bridging the gap: Should pharma step up as public health campaign funding declines?

With the decline in UK public health campaign funding, we have explored the unique opportunity presented to the pharmaceutical industry to step forward and do more to support the nation’s...

Say Communications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links